Featured

Zentraxa announce seed financing

Zentraxa are excited to announce capital investment from Future Planet Capital, Bristol Private Equity Club (BPEC) and Science Angel Syndicate to develop their innovative Zentide platform for engineering bespoke biomaterials.
Press Release.

University of Bristol Enterprise Sessions

Great to hear from our co-founder Martin Challand about his founder journey and some of the history of Zentraxa in conversation with Michele Barbour of University of Bristol.
You can watch the interview here.

Bioseed Conference 2022

We were delighted to attend OBN UK’s Bioseed conference on Jan 25th 2022, where our Executive Chair Jonathan Wogel gave a presentation showcasing our unique adhesion promoters and their application areas to potential new investors.
You can read more about the event on OBN’s LinkedIn page.

Our Executive Chair gives a presentation at OBN's Bioseed conference

UK Innovation Strategy

Fantastic to feature as a case study in the recent UK Innovation Strategy from the Department for Business, Energy & Industrial Strategy, and to see the government recognise the vital role funding organisations like UKI2S & Innovate UK play in encouraging innovation within UK industry.
Read the full paper here: UK Innovation Strategy 

News

UKI2S CEO Spotlight Article

As part of their CEO Spotlight blog, Jonathan spoke with @UKI2S, sharing his perspective on leadership, work ethic and how to achieve success.
Read the full article here: UKI2S article

BBSRC Grant Funding Article

Great to feature as a @BBSRC case study, recognising the importance of grant funding in establishing a firm technical and commercial foothold in the early stages of our companies development.
Read the full article here: BBSRC article

GENbio Synthetic Biology Article

@Zentraxa_Ltd featured in @GENbio as one of the examples of how synbio is transforming the petrochemical industry.
Read the article here: GENbio article

DSTL Collaboration

Zentraxa and DSTL have collaborated from the day the company was incorporated in March 2017. DSTL previously had a productive relationship with Dr Paul Race – one of the academic cofounders of Zentraxa, funding several PhD projects. When Zentraxa was in the early stages, this made DSTL an obvious partner to consider funding some of the feasibility studies on Zentraxa’s adhesive technology.

LinkedIn

Featured

Bioseed Conference 2022

We were delighted to attend OBN UK’s Bioseed conference on Jan 25th 2022, where our Executive Chair Jonathan Wogel gave a presentation showcasing our unique adhesion promoters and their application areas to potential new investors.
You can read more about the event on OBN’s LinkedIn page.

Our Executive Chair gives a presentation at OBN's Bioseed conference

UK Innovation Strategy

Fantastic to feature as a case study in the recent UK Innovation Strategy from the Department for Business, Energy & Industrial Strategy, and to see the government recognise the vital role funding organisations like UKI2S & Innovate UK play in encouraging innovation within UK industry.
Read the full paper here: UK Innovation Strategy 

News

UKI2S CEO Spotlight Article

As part of their CEO Spotlight blog, Jonathan spoke with @UKI2S, sharing his perspective on leadership, work ethic and how to achieve success.
Read the full article here: UKI2S article

BBSRC Grant Funding Article

Great to feature as a @BBSRC case study, recognising the importance of grant funding in establishing a firm technical and commercial foothold in the early stages of our companies development.
Read the full article here: BBSRC article

GENbio Synthetic Biology Article

@Zentraxa_Ltd featured in @GENbio as one of the examples of how synbio is transforming the petrochemical industry.

DSTL Collaboration

Zentraxa and DSTL have collaborated from the day the company was incorporated in March 2017. DSTL previously had a productive relationship with Dr Paul Race – one of the academic cofounders of Zentraxa, funding several PhD projects. When Zentraxa was in the early stages, this made DSTL an obvious partner to consider funding some of the feasibility studies on Zentraxa’s adhesive technology.

LinkedIn

Featured

Bioseed Conference 2022

We were delighted to attend OBN UK’s Bioseed conference on Jan 25th 2022, where our Executive Chair Jonathan Wogel gave a presentation showcasing our unique adhesion promoters and their application areas to potential new investors.
You can read more about the event on OBN’s LinkedIn page.

Our Executive Chair gives a presentation at OBN's Bioseed conference

UK Innovation Strategy

Fantastic to feature as a case study in the recent UK Innovation Strategy from the Department for Business, Energy & Industrial Strategy, and to see the government recognise the vital role funding organisations like UKI2S & Innovate UK play in encouraging innovation within UK industry.
Read the full paper here: UK Innovation Strategy 

News

UKI2S CEO Spotlight Article

As part of their CEO Spotlight blog, Jonathan spoke with @UKI2S, sharing his perspective on leadership, work ethic and how to achieve success.
Read the full article here: UKI2S article

BBSRC Grant Funding Article

Great to feature as a @BBSRC case study, recognising the importance of grant funding in establishing a firm technical and commercial foothold in the early stages of our companies development.
Read the full article here: BBSRC article

GENbio Synthetic Biology Article

@Zentraxa_Ltd featured in @GENbio as one of the examples of how synbio is transforming the petrochemical industry.

DSTL Collaboration

Zentraxa and DSTL have collaborated from the day the company was incorporated in March 2017. DSTL previously had a productive relationship with Dr Paul Race – one of the academic cofounders of Zentraxa, funding several PhD projects. When Zentraxa was in the early stages, this made DSTL an obvious partner to consider funding some of the feasibility studies on Zentraxa’s adhesive technology.

LinkedIn